Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries 2seventy bio, Inc. - Common Stock (NQ: TSVT ) 3.760 -0.100 (-2.59%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 25, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 396,789 Open 3.860 Bid (Size) 3.600 (10) Ask (Size) 3.940 (2) Prev. Close 3.860 Today's Range 3.720 - 3.900 52wk Range 1.535 - 11.29 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News 2seventy bio to Participate in Upcoming Investor Conferences May 23, 2024 From 2seventy bio, Inc. Via Business Wire TSVT Stock Earnings: 2seventy bio Meets EPS, Misses Revenue for Q1 2024 May 08, 2024 TSVT stock results show that 2seventy bio met analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. Via InvestorPlace Performance YTD -8.29% -8.29% 1 Month -11.94% -11.94% 3 Month -24.19% -24.19% 6 Month -5.29% -5.29% 1 Year -61.87% -61.87% More News Read More 2seventy bio Reports First Quarter Financial Results and Recent Operational Progress May 08, 2024 From 2seventy bio, Inc. Via Business Wire 2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024 May 03, 2024 From 2seventy bio, Inc. Via Business Wire A Preview Of 2seventy bio's Earnings March 04, 2024 Via Benzinga FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies April 19, 2024 Via Benzinga Exposures Product Safety FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer April 05, 2024 Via Benzinga Exposures Product Safety 2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron April 01, 2024 From 2seventy bio, Inc. Via Business Wire 2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors March 20, 2024 From 2seventy bio, Inc. Via Business Wire U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy April 05, 2024 From Bristol Myers Squibb Via Business Wire FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer March 18, 2024 Via Benzinga Exposures Product Safety 12 Health Care Stocks Moving In Monday's Pre-Market Session March 18, 2024 Via Benzinga Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session March 18, 2024 Via Benzinga Why Nuvei Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket March 18, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday March 18, 2024 Via InvestorPlace FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy March 15, 2024 From Bristol Myers Squibb Via Business Wire Why Cardlytics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket March 15, 2024 Via Benzinga Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley March 07, 2024 Via Benzinga TSVT Stock Earnings: 2seventy bio Misses EPS, Misses Revenue for Q4 2023 March 05, 2024 Via InvestorPlace 2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress March 05, 2024 From 2seventy bio, Inc. Via Business Wire 2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences March 01, 2024 From 2seventy bio, Inc. Via Business Wire Earnings Scheduled For March 5, 2024 March 05, 2024 Via Benzinga Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise February 27, 2024 Via Newsfile 2seventy bio to Participate in Upcoming Investor Conferences February 05, 2024 From 2seventy bio, Inc. Via Business Wire Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study February 05, 2024 From Bristol Myers Squibb Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.